Sarcopenia: Ammonia metabolism and hepatic encephalopathy

키워드

참고문헌 (88)

1. Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European working group on sarcopenia in older people", Age Ageing, 39, pp.412~423 (2010)
2. Janssen I, "Evolution of sarcopenia research", Appl Physiol Nutr Metab, 35, pp.707~712 (2010)
3. Montano-Loza AJ, "Clinical relevance of sarcopenia in patients with cirrhosis", World J Gastroenterol, 20, pp.8061~8071 (2014)
4. Tandon P, "Severe muscle depletion in patients on the liver transplant wait list : its prevalence and independent prognostic value", Liver Transpl, 18, pp.1209~1216 (2012)
5. Kim G, "Prognostic value of sarcopenia in patients with liver cirrhosis : a systematic review and meta-analysis", PLoS One, 12, pp.e0186990~ (2017)
6. Montano-Loza AJ, "Inclusion of sarcopenia within MELD(MELDSarcopenia)and the prediction of mortality in patients with cirrhosis", Clin Transl Gastroenterol, 6, pp.e102~ (2015)
7. Kang SH, "Impact of sarcopenia on prognostic value of cirrhosis : going beyond the hepatic venous pressure gradient and MELD score", J Cachexia Sarcopenia Muscle, 9, pp.860~870 (2018)
8. Musumeci G, "Sarcopenia and exercise “The State of the Art”", J Funct Morphol Kinesiol, 2, pp.40~ (2017)
9. Hanai T, "Sarcopenia impairs prognosis of patients with liver cirrhosis", Nutrition, 31, pp.193~199 (2015)
10. Durand F, "Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography", J Hepatol, 60, pp.1151~1157 (2014)
11. Montano-Loza AJ, "Muscle wasting is associated with mortality in patients with cirrhosis", Clin Gastroenterol Hepatol, 10, pp.166~173 (2012)[DOI]
12. Marchesini G, "Factors associated with poor health-related quality of life of patients with cirrhosis", Gastroenterology, 120, pp.170~178 (2001)
13. Krell RW, "Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation", Liver Transpl, 19, pp.1396~1402 (2013)
14. Merli M, "Muscle depletion increases the risk of overt and minimal hepatic encephalopathy : results of a prospective study", Metab Brain Dis, 28, pp.281~284 (2013)
15. DiMartini A, "Muscle mass predicts outcomes following liver transplantation", Liver Transpl, 19, pp.1172~1180 (2013)
16. Dasarathy S, "Posttransplant sarcopenia : an underrecognized early consequence of liver transplantation", Dig Dis Sci, 58, pp.3103~3111 (2013)
17. Tsien C, "Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent", Eur J Gastroenterol Hepatol, 25, pp.85~93 (2013)
18. Tsien C, "Post-liver transplantation sarcopenia in cirrhosis : a prospective evaluation", J Gastroenterol Hepatol, 29, pp.1250~1257 (2014)
19. Hayashi F, "Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis", Hepatol Res, 43, pp.1264~1275 (2013)
20. Madden AM, "Taste perception in cirrhosis : its relationship to circulating micronutrients and food preferences", Hepatology, 26, pp.40~48 (1997)
21. Romiti A, "Malabsorption and nutritional abnormalities in patients with liver cirrhosis", Ital J Gastroenterol, 22, pp.118~123 (1990)
22. Aoufi Rabih S, "Exocrine pancreatic insufficiency and chronic pancreatitis in chronic alcoholic liver disease : coincidence or shared toxicity", Pancreas, 43, pp.730~734 (2014)
23. Morrison WL, "Skeletal muscle and whole-body protein turnover in cirrhosis", Clin Sci(Lond), 78, pp.613~619 (1990)
24. Roubenoff R, "Sarcopenia : effects on body composition and function", J Gerontol A Biol Sci Med Sci, 58, pp.1012~1017 (2003)
25. Tajiri K, "Branched-chain amino acids in liver diseases", World J Gastroenterol, 19, pp.7620~7629 (2013)
26. Tsien C, "Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis", Hepatology, 61, pp.2018~2029 (2015)
27. Handelsman DJ, "Hypothalamic-pituitary-testicular function in end-stage nonalcoholic liver disease before and after liver transplantation", Clin Endocrinol(Oxf), 43, pp.331~337 (1995)
28. Grossmann M, "Low testosterone levels as an independent predictor of mortality in men with chronic liver disease", Clin Endocrinol(Oxf), 77, pp.323~328 (2012)
29. Orr R, "The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders : review of efficacy and safety", Drugs, 64, pp.725~750 (2004)
30. Sinclair M, "Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone : a randomized controlled trial", J Hepatol, 65, pp.906~913 (2016)
31. Beyer I, "Chronic low-grade inflammation and age-related sarcopenia", Curr Opin Clin Nutr Metab Care, 15, pp.12~22 (2012)
32. Thapaliya S, "Alcohol-induced autophagy contributes to loss in skeletal muscle mass", Autophagy, 10, pp.677~690 (2014)
33. García PS, "Briefreports : elevated myostatin levels in patients with liver disease : a potential contributor to skeletal muscle wasting", Anesth Analg, 111, pp.707~709 (2010)
34. Qiu J, "Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism", Proc Natl Acad Sci U S A, 110, pp.18162~18167 (2013)
35. Zietz B, "Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis", Eur J Gastroenterol Hepatol, 15, pp.495~501 (2003)
36. Drummond MJ, "Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling", J Appl Physiol(1985), 106, pp.1374~1384 (2009)
37. Garikipati DK, "Myostatin inhibits myosatellite cell proliferation and consequently activates differentiation : evidence for endocrine-regulated transcript processing", J Endocrinol, 215, pp.177~187 (2012)
38. Olde Damink SW, "Interorgan ammonia trafficking in liver disease", Metab Brain Dis, 24, pp.169~181 (2009)
39. Richardson AJ, "Ammonia production by human faecal bacteria, and the enumeration, isolation and characterization of bacteria capable of growth on peptides and amino acids", BMC Microbiol, 13, pp.6~ (2013)
40. Davila AM, "Intestinal luminal nitrogen metabolism : role of the gut microbiota and consequences for the host", Pharmacol Res, 68, pp.95~107 (2013)
41. Walker V, "Ammonia metabolism and hyperammonemic disorders", Adv Clin Chem, 67, pp.73~150 (2014)
42. Wright G, "Interorgan ammonia metabolism in liver failure : the basis of current and future therapies", Liver Int, 31, pp.163~175 (2011)
43. Schnabl B, "Linking intestinal homeostasis and liver disease", Curr Opin Gastroenterol, 29, pp.264~270 (2013)
44. Weiner ID, "Recent advances in understanding renal ammonia metabolism and transport", Curr Opin Nephrol Hypertens, 25, pp.436~443 (2016)
45. Dasarathy S, "Myostatin and beyond in cirrhosis : all roads lead to sarcopenia", J Cachexia Sarcopenia Muscle, 8, pp.864~869 (2017)
46. Nishikawa H, "Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis", J Cachexia Sarcopenia Muscle, 8, pp.915~925 (2017)
47. Qiu J, "Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis", Am J Physiol Endocrinol Metab, 303, pp.E983~ (2012)[DOI]
48. Kosenko E, "Sources of oxygen radicals in brain in acute ammonia intoxication in vivo", Brain Res, 981, pp.193~200 (2003)
49. Davuluri G, "Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of L-leucine in cirrhosis", J Hepatol, 65, pp.929~937 (2016)
50. Pakos‐Zebrucka K, "The integrated stress response", EMBO Rep, 17, pp.1374~1395 (2016)
51. Davuluri G, "Hyperammonaemia‐induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress", J Physiol, 594, pp.7341~7360 (2016)
52. Holeček M, "Branched‐chain amino acid supplementation in treatment of liver cirrhosis : updated views on how to attenuate their harmful effects on cataplerosis and ammonia formation", Nutrition, 41, pp.80~85 (2017)
53. Owen OE, "The key role of anaplerosis and cataplerosis for citric acid cycle function", J Biol Chem, 277, pp.30409~30412 (2002)
54. McDaniel J, "Hyperammonemia results in reduced muscle function independent of muscle mass", Am J Physiol Gastrointest Liver Physiol, 310, pp.G163~ (2016)[DOI]
55. Jacobsen EB, "Reduced mitochondrial adenosine triphosphate synthesis in skeletal muscle in patients with Child‐Pugh class B and C cirrhosis", Hepatology, 34, pp.7~12 (2001)
56. Poh Z, "A current review of the diagnostic and treatment strategies of hepatic encephalopathy", Int J Hepatol, 2012, pp.480309~ (2012)
57. Häussinger D, "Pathogenetic mechanisms of hepatic encephalopathy", Gut, 57, pp.1156~1165 (2008)
58. Lucero C, "The role of sarcopenia and frailty in hepatic encephalopathy management", Clin Liver Dis, 19, pp.507~528 (2015)
59. Kalaitzakis E, "Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis", Liver Int, 27, pp.1194~1201 (2007)
60. Huisman EJ, "Protein energy malnutrition predicts complications in liver cirrhosis", Eur J Gastroenterol Hepatol, 23, pp.982~989 (2011)
61. Meza-Junco J, "Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma", J Clin Gastroenterol, 47, pp.861~870 (2013)
62. Montano-Loza AJ, "Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver trans plantation", Liver Transpl, 20, pp.640~648 (2014)
63. Verna E, "Frailty, physical performance, and sarcopenia measures in patients awaiting liver transplantation predict mortality and postoperative complications", Am J Transplant, 14(Suppl 3), pp.742~ (2014)
64. Lai JC, "Frailty predicts waitlist mortality in liver transplant candidates", Am J Transplant, 14, pp.1870~1879 (2014)
65. Brusilow SW, "Hyperammonemic encephalopathy", Medicine(Baltimore), 81, pp.240~249 (2002)
66. Häussinger D, "Hepatic encephalopathy in chronic liver disease : a clinical manifestation of astrocyte swelling and low-grade cerebral edema", J Hepatol, 32, pp.1035~1038 (2000)
67. Guevara M, "Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis : a prospective study with time-dependent analysis", Am J Gastroenterol, 104, pp.1382~1389 (2009)
68. Seyan AS, "Changing face of hepatic encephalopathy : role of inflammation and oxidative stress", World J Gastroenterol, 16, pp.3347~3357 (2010)
69. Toshikuni N, "Nutrition and exercise in the management of liver cirrhosis", World J Gastroenterol, 20, pp.7286~7297 (2014)
70. Tandon P, "Exercise in cirrhosis : translating evidence and experience to practice", J Hepatol, 69, pp.1164~1177 (2018)
71. Fyfe JJ, "Interference between concurrent resistance and endurance exercise : molecular bases and the role of individual training variables", Sports Med, 44, pp.743~762 (2014)
72. Damas F, "A review of resistance training-induced changes in skeletal muscle protein synthesis and their contribution to hypertrophy", Sports Med, 45, pp.801~807 (2015)
73. Jones JC, "Exercise capacity and muscle strength in patients with cirrhosis", Liver Transpl, 18, pp.146~151 (2012)
74. Campillo B, "Influence of liver failure, ascites, and energy expenditure on the response to oral nutrition in alcoholic liver cirrhosis", Nutrition, 13, pp.613~621 (1997)
75. Okuda H, "Long-term nutritional assessment and quality of life in patients with cirrhosis taking a late evening snack", J Gastroenterol, 42, pp.186~187 (2007)
76. Matsumura T, "Oral administration of branched-chain amino acids activates the mTOR signal in cirrhotic rat liver", Hepatol Res, 33, pp.27~32 (2005)
77. Gluud LL, "Branched-chain amino acids for people with hepatic encephalopathy", Cochrane Database Syst Rev, (9), pp.CD001939~ (2015)
78. Kumar A, "Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis", Hepatology, 65, pp.2045~2058 (2017)
79. Balasubramaniyan V, "Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats", Am J Physiol Gastrointest Liver Physiol, 302, pp.G145~G152 (2012)
80. Rose CF, "Ammonia-lowering strategies for the treatment of hepatic encephalopathy", Clin Pharmacol Ther, 92, pp.321~331 (2012)
81. Young NR, "Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception", J Clin Endocrinol Metab, 77, pp.1028~1032 (1993)
82. Schlevogt B, "Testosterone treatment for patients with sarcopenia and liver cirrhosis", Z Gastroenterol, 55, pp.594~595 (2017)
83. Becker C, "Myostatin antibody(LY2495655)in older weak fallers : a proof-of-concept, randomized, phase 2 trial", Lancet Diabetes Endocrinol, 3, pp.948~957 (2015)
84. Han HQ, "Myostatin", activin pathway antagonism : molecular basis and therapeutic potential, 2013, pp.45, 2333~2347
85. Picardi A, "Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis", J Hepatol, 26, pp.191~202 (1997)
86. Nardelli S, "Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement", Clin Gastroenterol Hepatol, 15, pp.934~936 (2017)
87. Semsarian C, "Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signaling pathway", Nature, 400, pp.576~581 (1999)
88. Bergerson JT, "Liver transplantation arrests and reverses muscle wasting", Clin Transplant, 29, pp.216~221 (2015)

관련 논문AI추천